drugset

drugset / Trial / NCT02245776

Stem Cell Therapy in Incurable Neurological Disorders

NCT02245776 ↗

Phase 1 Withdrawn Neurogen Brain and Spine Institute

NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study was to analyze the benefit of autologous mononuclear cell therapy in incurable neurological disorders.

Timeline

Start: 2008-12
Primary completion: 2018-06
Completion: 2018-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Stem Cell	Cell therapy	—	Intrathecal

Indications